Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $50,000.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,000 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the transaction, the director now directly owns 299,695 shares of the company’s stock, valued at approximately $14,984,750. This trade represents a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Pro-Dex Stock Performance

Pro-Dex stock opened at $48.92 on Friday. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The firm has a market cap of $159.53 million, a P/E ratio of 24.34 and a beta of 0.68. Pro-Dex, Inc. has a 1-year low of $16.84 and a 1-year high of $59.60. The firm has a 50-day moving average of $39.78 and a 200-day moving average of $38.99.

Pro-Dex (NASDAQ:PDEX) last posted its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Sell-side analysts expect that Pro-Dex, Inc. will post 2 EPS for the current year.

Institutional Investors Weigh In On Pro-Dex

A number of large investors have recently modified their holdings of the stock. OMERS ADMINISTRATION Corp purchased a new position in shares of Pro-Dex in the 4th quarter valued at approximately $313,000. Millennium Management LLC bought a new stake in Pro-Dex in the fourth quarter worth $260,000. 683 Capital Management LLC purchased a new stake in shares of Pro-Dex in the fourth quarter worth $739,000. Northern Trust Corp raised its position in shares of Pro-Dex by 14.1% in the 4th quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock worth $1,672,000 after purchasing an additional 4,426 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Pro-Dex in the 4th quarter worth about $433,000. Institutional investors own 15.28% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Pro-Dex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.